According to data compiled by S&P Global Market Intelligence, Kymera Therapeutics (NASDAQ: KYMR) notched an almost 23% share ...

Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25 Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June ...

LKP Research is bullish on Cyient DLM has recommended buy rating on the stock with a target price of Rs 621 in its research ...

New area code 621 will begin servicing the Greater Houston area as of Jan. 23. Telephone customers requesting new phone numbers, a new service, adding a line or moving their service may be ...

Arkansas Governor Sarah Huckabee Sanders signed an estimated 621 bills into law, and now the 2025 session is pending recess.

The $621 million deal comes amid economic turmoil nationwide. As President Donald Trump’s tariffs destabilize the stock market and healthcare costs rise, Transcarent and Accolade’s merger ...

Get the latest car news, reviews, and features.

Digital health startup Transcarent on Tuesday announced it completed its acquisition of Accolade in a deal valued at roughly $621 million. Transcarent first announced the acquisition in ...

Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June 2025 Two parallel Phase 2b trials in AD and asthma planned to start in 4Q25 and 1Q26, respectively ...